Intracellular delivery with microfluidic vortex shedding (µVS)

Our microfluidic gene delivery platform can be used for gentle, scalable, and viral-free delivery of a range of molecules to several cell types, including human primary immune cells. Our team works with you to verify our platform for your specific applications.

How μVS enables Gene Delivery

μVS is a platform technology

Development pipeline

Info Device Proof of Concept Optimization
PMBCs or T cells
mRNA Toggle more info 85%
We demonstrate efficient mRNA expression of enhanced green fluorescent protein (EGFP) (e.g., 57.4 ± 6.8% of viable, recovery cells, mean ± stdev) after mRNA delivery to primary human T cells with high cell viability (e.g., 83.7 ± 0.7% of recovered cells), high cell recovery (e.g., 96.3 ± 1.1% of processed cells), and minimal alteration to T cell activation profile.
Cas9 RNPs (CRISPR) Toggle more info 60%
We are currently delivering Cas9 RNP complex to knock out and modify functional T cell markers. Please contact us for more information.
Plasmids Toggle more info 55%
We currently performing a delivery screen of plasmids ranging from 2-10kb into human primary T cells. In addition, we are developing a non-viral method for stable and persistent gene modification. Get in touch for more information.

Comparison to other technologies

μVS
Squeezing Electroporation Viruses
Yield High High Mid Variable
Speed High Mid High Slow
μL-scale Yes Yes Yes Yes
mL-scale Yes No Yes Yes
Perturbation No No Yes Yes
Flexibility Yes Low Yes Yes
Variability Low High Low High
Scalability High Mid High Low
Even Distribution Yes NR No No